All In MedTech

Device Trial Radar · NCT04877899

Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol

Mazankowski - Echo Go Discovery Protocol Retrospective LVEF/GLS Comparison

Last checked: Nov 19, 2026Latest source record: Sep 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

250

Planned (sponsor's estimate)

Start

Oct 8, 2020

Primary completion

Mar 31, 2021

Study completion Nov 30, 2021

Sponsor

Lead sponsor
Ultromics LtdNot on our public-company list
Sponsor type
Industry
Collaborators
Mazankowski Alberta Heart Institute
First posted
May 7, 2021

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 dimensional contrast and 2 dimensional non-contrast resting transthoracic echocardiograms for application in the assessment of patients undergoing chemotherapy with cardiotoxic drugs. This is a single-centre retrospective study which utilizes echocardiographic DICOM image and meta-data datasets received from a Canadian site. Data processed using the AI driven automated processing will be compared to conventionally acquired LVEF and GLS measurements and results will be analysed to determine accuracy and precision.

Conditions

  • Cardiotoxicity
  • Cancer

Interventions

  • EchoGoDevice

    EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician. EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the performance of automated EF and GLS measurements in resting transthoracic echocardiograms against conventional measurement acquisition.Time frame: Baseline
  2. Compare the performance of automated EF and GLS measurements in resting transthoracic echocardiograms against conventional measurement acquisition.Time frame: Follow up (up to 1 year)
  3. Compare the performance of automated EF and GLS measurements in resting transthoracic echocardiograms with and without the application of contrast agents.Time frame: Baseline

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mazankowski Alberta Heart Institute

    Edmonton, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.